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Background: During early treatment of haemorrhagic shock, cerebral perfusion pressure can 35 
be restored by small-volume resuscitation with vasopressors. Whether this therapy is 36 
improved with additional fluid remains unknown. We assessed the value of terlipressin and 37 
lactated Ringer’s solution (LR) on the early recovery of the microcirculation, tissue 38 
oxygenation, and mitochondrial and electrophysiological function in the rat cerebral cortex. 39 
Methods: Animals treated with LR replacing three times (3LR) the volume bled (n=26), 40 
terlipressin (n=27), terlipressin plus 1LR (n=26), 2LR (n=16), or 3LR (n=15) were compared 41 
with untreated (n=36) and sham-operated rats (n=17). In vivo confocal microscopy was used 42 
to assess cortical capillary perfusion, changes in tissue oxygen concentration, and 43 
mitochondrial membrane potential and redox state. Electrophysiological function was 44 
assessed by cortical somatosensory evoked potentials, spinal cord dorsum potential, and 45 
peripheral electromyography. 46 
Results: Compared with sham, haemorrhagic shock reduced the mean (standard deviation) 47 
area of perfused vessels [82% (10%) vs 38% (12%); P<0.001] and impaired oxygen 48 
concentration, mitochondrial redox state [99% (4%) vs 59% (15%) of baseline; P<0.001], 49 
and somatosensory evoked potentials [97% (13%) vs 27% (19%) of baseline].  50 
Administration terlipressin plus 1LR or 2LR was able to recover these measures, but 51 
terlipressin plus 3LR or 3LR alone were not as effective. Spinal cord dorsum potential was 52 
preserved in all groups, but no therapy protected electromyographic function. 53 
Conclusion: Resuscitation from haemorrhagic shock using terlipressin with small-volume 54 
LR was superior to high-volume LR, with regard to cerebral microcirculation, and 55 
mitochondrial and electrophysiological function. 56 
 57 
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Editor’s key points 59 
 Haemorrhage is the cause of up to 40% of deaths after trauma. 60 
 Early small volume resuscitation with terlipressin can restore cerebral perfusion after 61 
haemorrhagic shock. 62 
 The effect of additional fluid is unclear. 63 
 In an experimental haemorrhage model in rats, resuscitation with low but not high 64 
volume fluids plus terlipressin restored cerebral microcirculation and mitochondrial 65 
and electrophysiological function. 66 
 Optimum restoration of perfusion after haemorrhage is likely to reduce morbidity and 67 
mortality. 68 
 69 
Haemorrhage remains a major cause of early death, accounting for 30-40% of trauma 70 
mortality, with 33-56% of deaths occurring before arrival at hospital.1 Life-threatening loss 71 
of blood volume causes circulatory collapse.2 The consequent impairment in oxygen supply 72 
to the brain3 may cause neurological sequelae, most notably altered mentation (including loss 73 
of consciousness), seizures, and ischaemic stroke.2 4 5 The major mechanism is considered to 74 
be a cellular energy crisis arising from tissue hypoxia.3 6 7  In addition to a decrease in the 75 
cerebral macrocirculation, animal models of haemorrhagic shock suggest an impaired 76 
microcirculation8 and mitochondrial insufficiency9. As cell damage potentially starts at the 77 
onset of the haemodynamic decompensation6 7 10 11, blood supply to the brain must be 78 
restored rapidly. However, the optimal method for resuscitation is not established. Standard 79 
teaching is to restore adequate volaemia before commencing vasopressor agents. However, 80 
despite early fluid resuscitation to restore oxygen delivery to the tissues, cerebral perfusion 81 
pressure and oxygenation may fail to recover, especially if there is a persisting loss of 82 
vascular tone.3 12  83 
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Vasopressors can reduce the volume of crystalloid required to recover blood pressure 84 
after haemorrhagic shock and can rapidly recover cerebral perfusion pressure during 85 
prehospital care.3 13 Terlipressin, a synthetic analogue of vasopressin, has been proposed for 86 
the treatment of haemorrhagic shock.14 15 Compared with vasopressin, terlipressin is longer 87 
acting and has higher selectivity for the vasopressin V1 receptor.
15 16 Although studies in 88 
models of haemorrhage have demonstrated that terlipressin can improve cerebral perfusion 89 
pressure and tissue oxygenation12 17, their efficacy in protecting brain microcirculatory, 90 
mitochondrial and electrophysiological function is unknown. We therefore used confocal 91 
imaging to study the circulation and metabolic state of the brain during shock in vivo, and in 92 
real time. We postulated that small-volume resuscitation with terlipressin would be superior 93 
to more aggressive fluid replacement therapy in protecting mitochondrial and 94 
electrophysiological function, and perfused vessel density, in a rodent model of 95 





Experiments adhered to the Home Office (UK) 1986 Scientific Procedures Act and 99 
European Directive 2010/63/EU and results are reported according to relevant aspects of the 100 
Animal Research Reporting of In Vivo Experiments (ARRIVE) guidelines, with University 101 
College London Ethics Committee approval. 102 
Rats (male, in-house, Sprague Dawley, ~150g) were housed in groups of five in 103 
pathogen free cages with a 12 h light/dark cycle at 22°C with standard rat pellets available ad 104 
libitum. Rats were anaesthetised without recovery throughout the experiments using 105 
isoflurane delivered via a vaporiser (induction 5% in an induction cage, maintenance 1.5-2% 106 
via nose cone; IsoFlo, Abbott Labs, Maidenhead) while spontaneously breathing room air. 107 
Adequacy of anaesthesia was assessed by ensuring the absence of withdrawal reflex 108 
following paw and ear pinch, and by monitoring the values of heart rate, mean arterial 109 
pressure, and respiratory rate to noxious stimulation. Rectal temperature (36-37oC; 110 
underblanket, Harvard Apparatus, Cambridge), direct mean arterial pressure (MAP; left 111 
femoral artery connected to a pressure transducer WPI, Hitchin, Herts), respiratory rate and 112 
end-tidal carbon dioxide (ETCO2; via orotracheal intubation, Microcap, Oridion, Needham, 113 
MA, USA) were continuously monitored. The femoral vein was cannulated for fluid and 114 
drug administration. A craniotomy ~8 mm in diameter (centred at bregma -2 mm, lateral 2.5 115 
mm) was performed over the left somatosensory cortex and the animals either imaged using 116 
in vivo confocal microscopy, or assessed electrophysiologically, for the rest of the 117 
experiment.  118 
 119 
In vivo confocal microscopy  120 
The skull was fixed to a custom-made titanium bar using dental cement 121 
(Contemporary Ortho-Jet Powder, Lang Dental Manufacturing Co., Wheeling, IL, USA) 122 
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mixed with cyanoacrylate glue. The dura was removed, and platinum(II)-5,10,15,20-123 
tetrakis(2,3,4,5,6-pentafluorophenyl)porphyrin (PtPFPP)-based phosphorescent oxygen-124 
sensitive microbeads (Luxcel Biosciences, Cork, Ireland) applied to the cortex. The 125 
craniotomy was then sealed with a glass coverslip and petroleum jelly. Time-lapse 126 
fluorescence images were acquired with a laser-scanning confocal microscope (512 by 512 127 
pixels, optical slice 37.1μm; LSM 5 Pascal, Zeiss, Jena, Germany) to assess mitochondrial 128 
redox state by imaging endogenous flavoprotein fluorescence (excitation: 488nm; emission: 129 
505-570nm), and changes in local oxygen concentration (ex: 543nm; em: 650nm). At 130 
termination, intravenous fluorescein isothiocyanate-dextran 70 kDA (FITC-dextran; 0.5mg 131 
i.v.; ex: 488nm; em: 505-570nm; Sigma-Aldrich, Poole, Dorset) and topical 132 
tetramethylrhodamine methyl ester (TMRM; 1µM; ex: 543nm; em: 585nm; T-668, 133 
Molecular Probes, Invitrogen, Paisley, UK) were imaged to establish perfused vessel density 134 
and mitochondrial membrane potential, respectively. Images were processed using 135 
Fiji/Image J 1.48v (NIH, Bethesda, MD, USA). 136 
 137 
Electrophysiology  138 
The right tibial nerve was stimulated (DS2, Digitimer, Welwyn Garden City, Herts) 139 
percutaneously at the ankle (10Hz, twice supramaximal), with recording electrodes at the 140 
vertebral level T10/T11, and on the cortical dura (-2mm from bregma, 2.5mm from midline), 141 
with reference electrodes on nearby inactive tissue. Another recording electrode was placed 142 
over the ipsilateral metatarsal musculature, with a reference electrode in the third digit. The 143 
ground electrode was inserted under the lumbar skin. Recordings of the somatosensory 144 
evoked potentials, cord dorsum potentials and electromyographic signals were amplified 145 
(Neurolog System, Digitimer), and observed on an oscilloscope (Sigma 60, Nicolet, 146 
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Madison, WI, USA) and stored as averaged (n=20) compound action potentials. They were 147 
monitored as measures of cortical, spinal and muscular function, respectively. 148 
 149 
Study design 150 
After instrumentation, repeated administrations of 1.5 ml i.v. fluid challenges were 151 
given over 10 s every 5 min to ensure normovolaemia at baseline, until MAP failed to 152 
increase >10%.18 Animals were allowed to stabilize for 20 minutes before randomization 153 
envelopes were opened with allocation into one of the seven following groups: [i] not 154 
subjected to haemorrhagic shock (Sham; n=17); [ii] subjected to haemorrhagic shock, but not 155 
treated (Shock; n=36); [iii] lactated Ringer’s solution (LR) given at three times the volume of 156 
blood withdrawn (3LR; aggressive fluid resuscitation: n=26); [iv] bolus of 10µg 100g-1 of 157 
terlipressin alone (n=26) or combined with LR in low volumes of [v] one (Terli+1LR; n=26) 158 
or [vi] two times (Terli+2LR; n=26) the volume of blood withdrawn; or [vii] combined with 159 
LR in a high volume of three times (Terli +3LR; aggressive fluid resuscitation; n=26) the 160 
volume of blood withdrawn. The dose of terlipressin was titrated in a pilot study, starting 161 
from a dose previously described.14 162 
Haemorrhagic shock was achieved by removing blood from the arterial line, targeting 163 
a MAP of 40 mmHg, maintained for 30 minutes by withdrawing or re-infusing blood when 164 
necessary, before treatment.  165 
Data were recorded at baseline, after 30 minutes with MAP of 40 mmHg (shock), and 166 
at 5, 60, and 120 minutes (T5, T60 and T120) after treatment. After 150 min all surviving 167 
rats were culled at the end of the experiment. 168 
 169 
Statistical analysis 170 
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The sample size was calculated in preliminary experiments using a power analysis that 171 
indicated a minimum of 26 rats/group was required for a 95% chance (with 5% risk) to detect a 172 
difference between groups of 60%, 40%, and 46% in the cortical somatosensory evoked potentials 173 
(n=6/group), mitochondrial redox state (n=10 rats/group), and changes in tissue oxygen concentration 174 
(n=10 rats/group), respectively, considering a standard deviation of 8%, 15%, and 5%, respectively. 175 
Endogenous flavoprotein fluorescence was analysed by determining the ratio between the 176 
mean intensity of areas adjacent to veins and arteries (perivenular:periarterial ratio).19 20 The 177 
mean phosphorescence of the oxygen-sensitive beads was analysed by selecting up to six 178 
beads representing proximity to different vascular regions (the beads distribute randomly). 179 
The emission signals of flavoproteins and oxygen-sensitive beads analysed at each time-180 
point were compared with their corresponding emission signal at baseline. The TMRM 181 
images were analysed 150 minutes after shock, as described for flavoproteins. The FITC-182 
dextran fluorescence was analysed at 120 minutes after shock by determining the number of 183 
vessels crossing three equidistant horizontal and vertical lines, divided by the total length of 184 
the lines, and the area occupied by fluorescent vessels above a threshold brightness. In the 185 
electrophysiological recordings, the measurements at each time-point were compared with 186 
the measurement at baseline. Data were assessed for normality using Kolmogorov Smirnov 187 
test and were compared within and between groups using repeated measure two-way 188 
ANOVA followed by Tukey’s post hoc testing (GraphPad Prism 5.03, GraphPad Software 189 
Inc., La Jolla, CA, USA). The ‘last observation carried forward’ method was used when 190 
animals died before the end of the study. Pearson’s coefficient was calculated to assess 191 
correlation between variables. A 0-40 scoring system was calculated for each variable 192 
according to the percentage difference at T120/T150 compared with baseline/sham: (0) for 0-193 
20%, (1) for 21-40%, (2) for 41-60%, (3) for 61-80%, and (4) for 81-100%.  The sum of the 194 
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scores (0=worst, 40=best) was calculated to compare the effectiveness of each treatment. 195 





Bleeding and survival 199 
Ten rats from the Shock group were not included in the statistical analysis because 200 
they were used to generate the data upon which to base the power calculation. Only a single 201 
bolus of 1.5 ml fluid challenge was necessary in all rats to ensure normovolaemia at baseline. 202 
Removal of approximately 40% (approximately 4 ml) of the estimated blood volume (EBV) 203 
of each rat [EBV (ml) = 0.06 × BW (g) + 0.77]21 (approximately 10 ml) was necessary to 204 
induce haemorrhagic shock as defined by a MAP <40 mm Hg (Fig. 1a). Most animals died 205 
when not treated after shock (P<0.001 Shock vs Sham; Fig. 1b). Survival was higher in all 206 
treated groups; the most effective treatment was Terli+2LR (1 death; P<0.001 vs Shock).  207 
 208 
Cardiorespiratory variables 209 
Haemorrhagic shock caused a decrease in respiratory rate, ETCO2 and MAP in all 210 
groups compared with Sham (P<0.001; Fig. 1). This cardiorespiratory impairment did not 211 
recover at any time in the Shock group. MAP was significantly higher at T120 in all treated 212 
groups (P<0.001 vs Shock), although it remained lower compared with Sham (P<0.001). The 213 
respiratory rate was restored by all treatments at T120. However, the improvement in ETCO2 214 
was lower than in Sham, although higher than in Shock (P<0.001; Fig. 1). 215 
 216 
Cortical tissue oxygenation  217 
Haemorrhagic shock caused a significant decrease in tissue oxygenation near veins at 218 
T60 and T120 in the untreated Shock group compared with Sham (P<0.05; Fig. 2).  At these 219 
same timepoints, the perivenular tissue oxygenation was significantly higher following all 220 
treatments (P<0.05 vs Shock). Oxygenation near arteries was maintained throughout.  221 
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Cerebral vascular density 222 
The induction of haemorrhagic shock resulted in a highly significant decrease in both 223 
the density (0.05 (SD 0.01) vs 0.17 (0.01) n µm-2 for Sham, P<0.001) and percentage area of 224 
perfused vessels [38% (12%) vs 82% (10%) for Sham, P<0.001) at T120 (Fig. 3). Treatment 225 
with terlipressin and Terli+2LR improved both density and the percentage area of perfused 226 
vessels [0.14 (0.02) and 0.14 (0.02) n µm-2, P<0.001 vs Shock; 66% (14%) and 73% (9%), 227 
P<0.001 vs Shock, respectively) achieving results that were similar to Sham (Fig. 3). The 228 
other treatments were either inferior to Sham (3LR and Terli+1LR), or no better than 229 
untreated animals (Terli+3LR). 230 
 231 
Cerebral mitochondrial redox potential 232 
In all groups, haemorrhagic shock caused a significant decrease in flavoprotein 233 
fluorescence (i.e. increased reduced state) adjacent to veins, but fluorescence persisted in a 234 
‘halo’ around arteries (Fig. 4A), reflected by a reduction in the perivenular:periarterial 235 
fluorescence ratio (P<0.05; Fig. 4B). In the Shock group, the ratio was lower at T120 236 
compared with Sham [59% (16%) vs 99% (4%) of baseline; P<0.001; Fig. 4B]. All 237 
treatments were effective in increasing the fluorescence around veins at T5. At study end, 238 
administration of 3LR (73% (20%) of baseline; P<0.001) and Terli+3LR [74% (18%) of 239 
baseline; P<0.001] resulted in a lower perivenular:periarterial flavoprotein ratio compared 240 
with Sham, although higher than in Shock (P<0.05). At T120, animals treated with Terli, 241 
Terli+1LR and Terli+2LR showed ratios not significantly different to Sham [87% (20%), 242 






Cortical mitochondrial membrane potential 247 
Mitochondrial membrane potential, indicated by TMRM fluorescence (Fig. 5), 248 
revealed that most mitochondria were depolarised (non-functional) following haemorrhagic 249 
shock. Only the mitochondria located near arteries remaining polarised, resulting in arterial 250 
‘halos’ similar to those observed with flavoproteins. At 150 minutes after shock the 251 
perivenular:periarterial ratio was worse in the Shock group [0.28 (0.08); P<0.001], 3LR 252 
[0.39 (0.13); P<0.001] and Terli+3LR [0.34 (0.01); P<0.001], compared with Sham [0.97 253 
(0.09)]. No significant differences in the perivenular:periarterial TMRM ratio were observed 254 
in the Terli [0.98 (0.31)], Terli+1LR [0.76 (0.22)] and Terli+2LR [0.71 (0.04)] groups 255 
compared with Sham; values were also better than in Shock (all P<0.001). 256 
 257 
Electrophysiological function 258 
All bled groups decreased cortical function to approximately a third of baseline at 259 
shock (P<0.001 vs Sham). At T120, cortical function decreased further to 27±19% of 260 
baseline in Shock (Fig. 6a); aggressive fluid (Terli+3LR and 3LR groups) were not 261 
significantly better than no treatment. The Terli+1LR [73% (32%) of baseline] and 262 
Terli+2LR [95 (30%) of baseline] groups were indistinguishable from Sham [97% (13%) 263 
from baseline], and higher than in Shock (P<0.001) at T120. A decrease was seen in peak-to-264 
peak muscular function amplitude (P<0.001); no treatments restored this to baseline values 265 
(Fig. 6a). In the Terli+1LR (P<0.05) and Terli+2LR (P<0.001) groups, the peak-to-peak 266 
amplitude was greater at T120 compared with Shock. The amplitude of the cord dorsum 267 
potential (Fig. 6) and the peak latency of all potentials did not change significantly in any 268 





Correlations and scores for effectiveness of the treatments 272 
A positive correlation was seen between the drop in MAP, and changes in flavoprotein 273 
(r2=0.84, P=0.0006) and TMRM signals (r2=0.57, P=0.0484), total perfused vessel density 274 
(r2=0.69, P=0.0055), area fraction of perfused vessels (r2=0.78, P=0.0019), and changes in 275 
cortical function (r2=0.72, P=0.0032), at T120. At T120, the changes in fluorescence of the 276 
perivenular oxygen-sensitive microbeads showed a weak but significant correlation with 277 
MAP (r2=0.54; P=0.0185), and with changes in flavoprotein fluorescence (r2=0.60; 278 
P=0.0235) and periarterial oxygen-sensitive microbeads (r2=0.63; P=0.0187) (Table 2). In 279 
addition, changes in fraction of perfused vessels were correlated with changes in flavoprotein 280 
fluorescence (r2=0.90, P=0.0003), TMRM signals (r2=0.89, P=0.0172), and somatosensory 281 
evoked potentials (r2=0.82, P=0.0018). 282 
The Terli+2LR (score of 33), Terli+1LR (score of 27), and Terli (score of 27) were the 283 
most effective treatments to improve the variables assessed. Scores of effectiveness were 40 284 






We describe the consequences of different resuscitation regimens immediately after 289 
haemorrhagic shock, focusing on the vasculature, oxygenation and function of the nervous 290 
system. Although the cerebral cortex is profoundly affected by haemorrhagic shock, with a 291 
dramatic reduction in perfusion of the smaller vessels accompanied by loss of mitochondrial 292 
function, it is nonetheless possible to restore perfusion, mitochondrial and neurological 293 
function by the timely administration of effective therapy.  294 
All treatments improved survival within the time course of the study. While 295 
administration of terlipressin was generally associated with improvement in the measured 296 
variables, the combination of terlipressin and aggressive fluid (i.e. Terli+3LR) did not. 297 
Whether this is due to negative cardiovascular effects and/or other causes remains uncertain. 298 
If the amplitude of the cortical evoked potential is taken as the benchmark of a good 299 
outcome, this was optimally achieved by Terli+2LR, and associated with a better 300 
mitochondrial membrane potential (required for ATP production) and well-perfused blood 301 
vessels. Mitochondrial and neuronal dysfunction were found to correlate with impaired 302 
capillary perfusion, illuminating an earlier discrepancy described between perfusion and total 303 
cerebral flow.8    304 
Of note, we found that mitochondrial function was selectively preserved in cortical 305 
tissue surrounding arterioles, which reveals a profound spatial inhomogeneity in the 306 
vulnerability of cortical tissue to a reduced cerebral microcirculation.19 20 A major reduction 307 
in oxygen supply to tissues remote from arteries can compromise oxidative phosphorylation 308 
and thus cellular ATP availability. This may affect the ability to maintain neuronal 309 
excitability and signalling;22 in agreement we also report a loss of cortical evoked potential 310 
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during shock. The status of both mitochondrial23 and neuronal24-26 function are known to 311 
have a close correlation with prognosis following shock.   312 
The failure to recover capillary perfusion by standard aggressive fluid resuscitation is 313 
perhaps not unexpected, given the failure of all therapies to achieve persistent restoration of 314 
arterial pressure. This failure may result from the extravasation into interstitial tissues of 315 
large amounts of isotonic crystalloids,27 causing brain swelling and thus compression within 316 
the skull, diminishing the cerebral perfusion pressure gradient.3 9 Arguably the most 317 
important consequence is mitochondrial dysfunction, perhaps related to increased nitric 318 
oxide production28 combined with reduced oxygen transport to mitochondria. This is 319 
particularly pertinent in shock states as nitric oxide competes with oxygen for the same 320 
binding site on mitochondrial Complex IV (cytochrome oxidase).28 Thus a rise in 321 
oxygenation does not necessarily signal a good outcome, but perhaps a failure of oxygen 322 
utilization.  323 
Small volume resuscitation has been proposed to avoid tissue oedema resulting from 324 
aggressive fluid resuscitation.29 Indeed, animal models of haemorrhage have demonstrated 325 
that terlipressin can restore cerebral perfusion pressure without increasing intracranial 326 
pressure,17 namely conditions required for an adequate microcirculation.  An alternative 327 
approach has been to provide perfusion by small-volume isotonic fluid such as LR in 328 
combination with terlipressin, which results in a more sustained improvement in arterial 329 
pressure. The vasoconstrictor effect of terlipressin, which can be given by a single bolus 330 
injection, makes it a simple and practical treatment for use until hospital care is available. 331 
Terlipressin improved survival in models of haemorrhagic shock,14-16 as we observed in the 332 
present study.  The main adverse effect of terlipressin is the increase in systemic vascular 333 
resistance that can further compromise both heart function and local tissue blood flow.30 334 
However, in a porcine model of haemorrhagic shock terlipressin was effective in 335 
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redistributing blood flow to recover cerebral perfusion pressure and oxygenation without 336 
deleterious effects on systemic perfusion.17 Accordingly, in human patients with 337 
catecholamine-resistant shock, terlipressin has been successfully used to improve cerebral 338 
perfusion pressure and oxygenation in cases of septic shock,31 acute liver failure,32, and 339 
traumatic brain injury.33   340 
A benefit of terlipressin on the brain was the higher number of perfused vessels when 341 
associated with LR in small volumes. This indicates that terlipressin can reduce the volume 342 
of LR necessary for resuscitation, thereby reducing the adverse effects of aggressive volume 343 
resuscitation, such as cerebral expansion and compression. Studies using other vasopressors, 344 
such as norepinephrine did not report improved cerebral perfusion pressure and oxygenation 345 
in models of haemorrhagic shock.7 34 346 
Study limitations include the fact that the study was focused on the effects of a 347 
vasopressor following haemorrhagic shock, which resulted in the absence of a groups treated 348 
with LR in a volume of two and three times the volume of blood removed to induce 349 
haemorrhagic shock. The absence of correlation between vessel perfusion and tissue 350 
oxygenation could be attributed to the fact that the method used to assess vessel perfusion 351 
could not differentiate arteries from veins as in the tissue oxygenation assessment. Finally, 352 
the data were limited to two hours after shock in an attempt to reflect a common prehospital 353 
resuscitation regimen, and long-term outcomes remain unknown. 354 
The significant recovery of cerebral mitochondrial and electrophysiological function 355 
by administration of terlipressin and small volumes of LR was associated with restoration of 356 
a near-normal density of perfused cortical vessels and cortical mitochondrial function, at two 357 
hours, with recovery of cortical-evoked potentials. It is reasonable to expect that optimal 358 
resuscitation therapy may avoid the complications of haemorrhagic shock encephalopathy.  359 
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None of the other therapies tested were as effective as the combination of terlipressin and 360 
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Figure 1. (a) Data showing mean bodyweight, mean estimated blood volume withdrawn to 510 
induce haemorrhagic shock, and mean time until death after shock. EBV: estimated blood 511 
volume. (b) Kaplan Meier curve and changes in mean arterial pressure, respiratory rate and 512 
end-tidal carbon dioxide induced by haemorrhagic shock, and treatment with LR, terlipressin 513 
and combined treatments of LR plus terlipressin. *vs Sham (at least P<0.05); + vs Not treated 514 





Figure 2. Changes in phosphorescence of oxygen-sensitive microbeads according to their 518 
location relative to the veins and arteries throughout the study. * vs Sham of the same time-519 





Figure 3. Vasculature of the cerebral cortex assessed by FITC-dextran administered 523 
intravenously in rats after 120 minutes of haemorrhagic shock. (a) Total perfused vessel 524 
density reflects the quantity of blood vessels with flow. (b) Representative in vivo confocal 525 
images of the cortical vasculature revealed by the FITC-dextran. (c) Area fraction of blood 526 
vessels represents the relative area covered by the FITC-dextran fluorescence. The marker 527 
was administered intravenously and, therefore, was only present in perfused blood vessels. 528 
The images of the Not treated Shock, 3LR and Terli+3LR groups show notably fewer vessels 529 
than Sham. Images of rats receiving Terli and Terli+2LR showed no significant differences 530 







Figure 4. Changes in endogenous flavoprotein fluorescence induced by haemorrhagic shock 534 
followed by different treatments. (a) In vivo confocal images of rat cerebral cortex showing 535 
mitochondrial function revealed by the intrinsic fluorescence of oxidized endogenous 536 
flavoprotein (green). Whereas the normal brain displays a quite uniform green fluorescence 537 
for flavoproteins before haemorrhagic shock, the fluorescence was lost almost everywhere 538 
except for a ‘halo’ around arteries after shock.  All treatments gave some recovery of 539 
fluorescence at 5 minutes, but the recovery after some treatments was only temporary.  At 540 
120 minutes after shock, the flavoprotein fluorescence persisted only in the Terli and 541 
Terli+2LR groups. (b) Changes in the perivenular:periarterial ratio of the endogenous 542 
flavoprotein fluorescence throughout the study. * vs Sham (at least P<0.05); + vs Not treated 543 
Shock group (at least P<0.05). 544 
 545 
 546 
Figure 5. Graph and confocal in vivo images showing changes in mitochondrial membrane 547 
potential revealed by TMRM in the cerebral cortex of rats at 150 minutes after haemorrhagic 548 
28 
 
shock.  TMRM fluorescence only accumulates within mitochondria possessing a membrane 549 
potential.  In the not-treated Shock group many mitochondria were depolarized, and 550 
presumably non-functional; only mitochondria near arteries remained polarized, resulting in 551 
the formation of periarterial TMRM ‘halos’.  A similar pattern of periarterial halos was 552 
observed in rats treated with 3LR and Terli+3LR, though polarized mitochondria were 553 
distributed more widely in rats treated with Terli, Terli+1LR and Terli+2LR: indeed, rats 554 
treated with these regimens had a spread of polarized mitochondria that was not significantly 555 






Figure 6. Changes in the amplitude of the somatosensory cortical evoked potential, cord 560 
dorsum potential and electromyography in response to haemorrhagic shock and the different 561 
treatments. * vs Sham (at least P<0.05); + vs Not-treated Shock group (at least P<0.05). 562 
